Mathieu Y. Brunet, Adam McGuinness, Kenny Man, Marie-Christine Jones, Sophie C. Cox
{"title":"Harnessing μ-X-Ray Fluorescence Spectroscopy as a Tool to Assess Extracellular Vesicle-Induced Biomineralization","authors":"Mathieu Y. Brunet, Adam McGuinness, Kenny Man, Marie-Christine Jones, Sophie C. Cox","doi":"10.1002/anbr.202400184","DOIUrl":null,"url":null,"abstract":"<p>\nBone cell-derived extracellular vesicles (EVs) have been increasingly investigated as novel acellular strategies for bone regeneration due to their pro-regenerative potency. The evaluation of such bone repair enhancement strategies commonly lies in the assessment of cell-mediated mineral deposition, associated with destructive and nonhigh-throughput methods. Herein, a robust methodology is presented to assess the osteogenic potential of an EV therapy using μ-X-ray fluorescence spectroscopy (μ-XRF). Mineralizing osteoblast-derived EVs (MO-EVs) are isolated from conditioned media via ultracentrifugation and comprehensively characterized. Their pro-osteogenic potency is validated via alkaline phosphatase activity, alizarin red, and picrosirius red staining for the evaluation of calcium and matrix deposition, respectively. μ-XRF is first employed to quantify calcium and phosphorous levels as markers of minerals generating 2D elemental maps of the cultures. The in-depth downstream analysis of the elemental maps reveals that MO-EVs modulate mineralization in a time- and concentration-dependent manner as MO-EV concentration from 5 μg mL<sup>−1</sup> significantly increases mineral coverage and increases calcium/phosphate levels in mineralized phases. Together, these results demonstrate the potential of μ-XRF, allowing the examination of elemental levels, mineral coverage, and chemical phases in a single process and thus, offering a new platform for the therapeutic screening of osteogenic technologies with a resolution accommodating biological workflows.</p>","PeriodicalId":29975,"journal":{"name":"Advanced Nanobiomed Research","volume":"5 6","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/anbr.202400184","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced Nanobiomed Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/anbr.202400184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Bone cell-derived extracellular vesicles (EVs) have been increasingly investigated as novel acellular strategies for bone regeneration due to their pro-regenerative potency. The evaluation of such bone repair enhancement strategies commonly lies in the assessment of cell-mediated mineral deposition, associated with destructive and nonhigh-throughput methods. Herein, a robust methodology is presented to assess the osteogenic potential of an EV therapy using μ-X-ray fluorescence spectroscopy (μ-XRF). Mineralizing osteoblast-derived EVs (MO-EVs) are isolated from conditioned media via ultracentrifugation and comprehensively characterized. Their pro-osteogenic potency is validated via alkaline phosphatase activity, alizarin red, and picrosirius red staining for the evaluation of calcium and matrix deposition, respectively. μ-XRF is first employed to quantify calcium and phosphorous levels as markers of minerals generating 2D elemental maps of the cultures. The in-depth downstream analysis of the elemental maps reveals that MO-EVs modulate mineralization in a time- and concentration-dependent manner as MO-EV concentration from 5 μg mL−1 significantly increases mineral coverage and increases calcium/phosphate levels in mineralized phases. Together, these results demonstrate the potential of μ-XRF, allowing the examination of elemental levels, mineral coverage, and chemical phases in a single process and thus, offering a new platform for the therapeutic screening of osteogenic technologies with a resolution accommodating biological workflows.
期刊介绍：
Advanced NanoBiomed Research will provide an Open Access home for cutting-edge nanomedicine, bioengineering and biomaterials research aimed at improving human health. The journal will capture a broad spectrum of research from increasingly multi- and interdisciplinary fields of the traditional areas of biomedicine, bioengineering and health-related materials science as well as precision and personalized medicine, drug delivery, and artificial intelligence-driven health science.
The scope of Advanced NanoBiomed Research will cover the following key subject areas:
▪ Nanomedicine and nanotechnology, with applications in drug and gene delivery, diagnostics, theranostics, photothermal and photodynamic therapy and multimodal imaging.
▪ Biomaterials, including hydrogels, 2D materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics (such as artificial cells, exosomes and extracellular vesicles), as well as all organic and inorganic materials for biomedical applications.
▪ Biointerfaces, such as anti-microbial surfaces and coatings, as well as interfaces for cellular engineering, immunoengineering and 3D cell culture.
▪ Biofabrication including (bio)inks and technologies, towards generation of functional tissues and organs.
▪ Tissue engineering and regenerative medicine, including scaffolds and scaffold-free approaches, for bone, ligament, muscle, skin, neural, cardiac tissue engineering and tissue vascularization.
▪ Devices for healthcare applications, disease modelling and treatment, such as diagnostics, lab-on-a-chip, organs-on-a-chip, bioMEMS, bioelectronics, wearables, actuators, soft robotics, and intelligent drug delivery systems.
with a strong focus on applications of these fields, from bench-to-bedside, for treatment of all diseases and disorders, such as infectious, autoimmune, cardiovascular and metabolic diseases, neurological disorders and cancer; including pharmacology and toxicology studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
